Jaguar Health Inc rises amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 Dec 25
Source: PRE 14A
Jaguar Health Inc saw a significant price increase of 17.09%, crossing above its 20-day SMA, despite a slight decline in the broader market indices.
The Nasdaq-100 and S&P 500 are down 0.14% and 0.05%, respectively, indicating a general market weakness. However, Jaguar Health's stock movement suggests a potential sector rotation or specific investor interest in the company.
This upward movement could reflect growing confidence in Jaguar Health's future prospects, especially as the company prepares for upcoming events that may attract investor attention.
Analyst Views on JAGX
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
